Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with -$539000.0 as the latest value for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 549.17% year-over-year to -$539000.0; the TTM value through Mar 2026 reached -$619000.0, down 135.68%, while the annual FY2025 figure was $280000.0, 66.51% down from the prior year.
  • Asset Writedowns and Impairment hit -$539000.0 in Q4 2025 for Phathom Pharmaceuticals, down from -$80000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $899000.0 in Q1 2025 and bottomed at -$539000.0 in Q4 2025.